Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EC research programme positive for devices industry:

This article was originally published in Clinica

Executive Summary

Eucomed, the European medical device industry association, has welcomed enthusiastically the European Commission's proposal for its next research programme, confident that it promises "fertile conditions" in which the medical devices industry will innovate and thrive. "We are pleased to see that a particular emphasis has been placed on the development and validation of new therapies, diagnostic tools and technologies," director general Maurice Wagner, has commented on the 7th Framework Programme for Research 2007-2013. The industry association has expressed its approval at seeing nanotechnology and emerging technologies as receiving particular attention, using the opportunity to highlight the potential that nanotechnology has in terms of future cancer treatment.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT054801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel